Anthropic CEO Dario Amodei told STAT+ that AI’s “decade’s worth of progress per year” vision for biotech and pharma may not arrive on the originally expected timeline. At an Anthropic event unveiling Claude Science for biologists and pharmaceutical teams, Amodei said current systems cannot yet deliver ten-years-per-year acceleration due to model limitations, the time researchers need to learn effective workflows, and the slower pace of infrastructure and regulatory changes required to integrate AI into discovery and development. The remarks matter for biotech operators because they frame near-term adoption as workflow augmentation rather than immediate, full-spectrum productivity replacement. The story also situates Claude Science as an operational entry point—positioning AI as a tool for biologists now, with broader impact dependent on regulators and implementation maturity.